“We aim to make molecular diagnostics based on RT-PCR technology mainstream in India”
Bio Spectrum
|September 2020
Backed by Serum Institute of India, Pune based startup Mylab Discovery Solutions is aggressively launching new products in the diagnostic testing space to overcome the challenges posed by the pandemic. After raising funds from the Department of Biotechnology (DBT) and few private investors, the Mylab team has recently developed a fully-automated sample to-PCR-ready system for molecular diagnostics, which is a first in India. Founded in 2016, it is the first company in Asia and second company worldwide to develop and manufacture FDA approved ID-NAT kits for accurate detection of HIV, HBV, HCV and other infections. BioSpectrum India got in touch with Hasmukh Rawal, Managing Director, Mylab Discovery Solutions to find out more about the initiatives being taken up by the startup to combat COVID-19. Edited excerpts;
Hasmukh Rawal, Managing Director, Mylab Discovery Solutions, Pune
What are the key advantages being offered by the Compact XL system compared to the conventional RT-PCR testing systems?
Compact XL is a sample-to-PCR ready machine for molecular diagnostics that eliminates the huge infrastructure cost of setting up a molecular lab. It is designed to automate lab operations from sample handing to RT-PCR tube preparation. It has flexibility to test multiple parameters with multiple samples at the same time, a never before the feature. With 32 separate channels, dual-deck facility, automated barcode reading, auto fed protocol, self-sanitization, and laboratory information management system (LIMS) connectivity defines Compact XL, as a complete walk-away system. It is a cartridge-based machine and can test multiple samples concurrently. It can be used for a wide range of RNA/DNA-based tests including COVID-19 RT-PCR tests. The machine can take a variety of sample types such as plasma, tissue, sputum, and swab. Other benefits include: Save on real estate costs- no need for multiple rooms and 1000+ sq ft of space. Compact XL reduces footprint to a single room of 100 sqft; Reduced manpower- a traditional lab needs 3-4 skilled molecular biologists. Compact XL allows you to run a lab with just 1 technician; Less Equipment & Consumables- significantly cost-saving on dozens of small equipment and consumables, made obsolete by Compact XL; Zero Manual Error- an automated process with no manual intervention. Accurate material handling and process adherence for reliable results; Low maintenance- Compact XL is a hassle and maintenance free system to save you costs in short and long term. To make India self-reliant in advanced diagnostics, Compact XL is our most ambitious project to date.
このストーリーは、Bio Spectrum の September 2020 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Bio Spectrum からのその他のストーリー
Bio Spectrum
India's Strategic Shift Towards High-Quality, Low-Cost MedTech
India's healthcare infrastructure continues to face significant strain from the rising prevalence of non-communicable diseases (NCDs), contributing around 66 per cent of the mortalities in the country, underscoring the need for scalable continuous monitoring, early diagnosis, and therapeutic devices. Yet, advanced imaging systems, analysers, surgical tools, or robotic devices remain very expensive due to import reliance, high logistics costs, and maintenance/ service contracts. Segments showing strongest traction today are diagnostics (point-of-care devices, rapid tests, compact imaging devices), remote monitoring/wearable devices, and therapeutic devices such as surgical robotic systems, renal care systems, and wound care devices.
4 mins
December 2025
Bio Spectrum
How India's Diabetes Crisis is Driving Med Devices Market
A growing diabetic population in India is a blessing for the care devices market. Both Indian and global diabetes care devices have taken this growing demand for various devices, kits as an opportunity to expand their market share. But the scope in rural areas seems a bit challenging for various companies due to less awareness about the disease, affordability etc. Let's look at this growing diabetes care devices market.
9 mins
December 2025
Bio Spectrum
Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility
Thermo Fisher Scientific's expanded Research and Development (R&D) Centre of Excellence was inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM).
1 min
December 2025
Bio Spectrum
Motorica strengthens India presence with appointment of Kavinder Beniwal as COO
Motorica, a Delhi-based medtech company specialising in assistive technologies and medical cybernetics, has announced the appointment of Kavinder Beniwal as Chief Operational Officer (COO) of Motorica India.
1 min
December 2025
Bio Spectrum
Cabinet approves major expansion of PG and UG medical education capacity
Union Cabinet chaired by the Prime Minister Narendra Modi has approved the Phase-Ill of the Centrally Sponsored Scheme (CSS) for strengthening and upgradation of existing State Government/ Central Government Medical Colleges/Standalone PG Institutes/ Government Hospitals for increasing 5,000 PG seats and extension of the CSS for upgradation of existing government medical colleges for increasing 5,023 MBBS seats with an enhanced cost ceiling of Rs 1.5 crore per seat.
1 min
December 2025
Bio Spectrum
Dr Sharvil Patel steps in as Indian Pharmaceutical Alliance President
The Indian Pharmaceutical Alliance (IPA) has announced a leadership transition, with Dr Sharvil Patel, Managing Director of Zydus Lifesciences and former Vice President of IPA, assuming the role of President.
1 min
December 2025
Bio Spectrum
PAG-led Sekhmet Pharmaventures announces appointment of Mukesh Agarwal as CFO
Hyderabad-based Sekhmet Pharmaventures, a fast-emerging global API/CDMO player led by leading Asia-focused investment firm PAG, has announced the appointment of Mukesh Agarwal as its new Chief Financial Officer (CFO).
1 min
December 2025
Bio Spectrum
Monash University Malaysia and Tata Chemicals forge healthcare researchfocused partnership
The importance of gastrointestinal health is a key focus for researchers and innovators, as highlighted by the partnership between Monash University Malaysia and Tata Chemicals Limited.
1 min
December 2025
Bio Spectrum
"India has the talent and ambition to lead globally in advanced therapies, biologics, and oncology"
Thermo Fisher Scientific has recently announced plans to make significant investments in India's biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, i.e. Bioprocess Design Center (BDC), and Customer Experience Center (CEC). In addition, the company has invested more than Rs 160 crore this year to expand its R&D facility in Bengaluru. For further understanding on these new developments, BioSpectrum spoke in detail to Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific. Edited excerpts;
4 mins
December 2025
Bio Spectrum
"AI is a transformative enabler that's reshaping how science is conducted in labs"
2025 witnessed multiple new initiatives taken by Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, for the Indian market. These initiatives included establishment of an India Solutions Center in Manesar; and a Biopharma Experience Center in Hyderabad. 2025 also saw Nandakumar Kalathil stepping in as the new Country General Manager for Agilent India. With over 25 years of experience in the analytical industry, Nanda brings extensive expertise in leadership, team management, and customer relations. To find out more about the company's growth plans in 2026 in India, BioSpectrum interacted with Nandakumar Kalathil, Country General Manager for Agilent India in detail. Edited excerpts:
4 mins
December 2025
Translate
Change font size

